mTOR Inhibitors in Castration-Resistant Prostate Cancer: A Systematic Review
Published 2016 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
mTOR Inhibitors in Castration-Resistant Prostate Cancer: A Systematic Review
Authors
Keywords
Docetaxel, Androgen Receptor, Gefitinib, Everolimus, mTOR Inhibitor
Journal
Targeted Oncology
Volume 12, Issue 1, Pages 47-59
Publisher
Springer Nature
Online
2016-08-09
DOI
10.1007/s11523-016-0453-6
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Targeting the androgen receptor in metastatic castrate-resistant prostate cancer: A review
- (2016) Archana Anantharaman et al. UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS
- Targeting molecular resistance in castration-resistant prostate cancer
- (2015) Thenappan Chandrasekar et al. BMC Medicine
- Everolimus combined with gefitinib in patients with metastatic castration-resistant prostate cancer: Phase 1/2 results and signaling pathway implications
- (2015) Dana E. Rathkopf et al. CANCER
- Integrative Clinical Genomics of Advanced Prostate Cancer
- (2015) Dan Robinson et al. CELL
- A Phase I Study of Everolimus and Docetaxel in Patients With Castration-Resistant Prostate Cancer
- (2015) Kevin D. Courtney et al. Clinical Genitourinary Cancer
- Targeting PI3K/Akt/mTOR signaling pathway in the treatment of prostate cancer radioresistance
- (2015) Lei Chang et al. CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
- Persistent androgen receptor addiction in castration-resistant prostate cancer
- (2015) Michael T. Schweizer et al. Journal of Hematology & Oncology
- Temsirolimus Maintenance Therapy After Docetaxel Induction in Castration-Resistant Prostate Cancer
- (2015) U. Emmenegger et al. ONCOLOGIST
- Impact of metformin on clinical outcomes among men with prostate cancer: a systematic review and meta-analysis
- (2015) A D Raval et al. PROSTATE CANCER AND PROSTATIC DISEASES
- Phase II Trial of Carboplatin, Everolimus, and Prednisone in Metastatic Castration-resistant Prostate Cancer Pretreated With Docetaxel Chemotherapy: A Prostate Cancer Clinical Trial Consortium Study
- (2015) Ulka Vaishampayan et al. UROLOGY
- Reciprocal feedback inhibition of the androgen receptor and PI3K as a novel therapy for castrate-sensitive and -resistant prostate cancer
- (2015) Wenqing Qi et al. Oncotarget
- PI3K-AKT-mTOR signaling in prostate cancer progression and androgen deprivation therapy resistance
- (2014) AndrewC Hsieh et al. ASIAN JOURNAL OF ANDROLOGY
- Metformin Activates AMP-activated Protein Kinase by Promoting Formation of the αβγ Heterotrimeric Complex
- (2014) Shumei Meng et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Crosstalking between Androgen and PI3K/AKT Signaling Pathways in Prostate Cancer Cells
- (2014) Suk Hyung Lee et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Should we give metformin to all men with CRPC?
- (2014) Melanie Clyne Nature Reviews Urology
- Preserving Flow in Liver Transplant Recipients: mTOR Inhibitors Everolimus and Sirolimus Are Not Peas From a Pod
- (2013) M. Bhat et al. AMERICAN JOURNAL OF TRANSPLANTATION
- Comparative Study of Rapamycin and Temsirolimus Demonstrates Superimposable Anti-Tumour Potency on Prostate Cancer Cells
- (2013) Paolo Fagone et al. BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY
- A phase II study evaluating the toxicity and efficacy of single-agent temsirolimus in chemotherapy-naïve castration-resistant prostate cancer
- (2013) K Kruczek et al. BRITISH JOURNAL OF CANCER
- Tolerability, safety and pharmacokinetics of ridaforolimus in combination with bicalutamide in patients with asymptomatic, metastatic castration-resistant prostate cancer (CRPC)
- (2013) Hielke J. Meulenbeld et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- A Phase II Trial of Temsirolimus in Men With Castration-Resistant Metastatic Prostate Cancer
- (2013) Andrew J. Armstrong et al. Clinical Genitourinary Cancer
- Targeting the PI3K/Akt/mTOR pathway in castration-resistant prostate cancer
- (2013) Rhonda L Bitting et al. ENDOCRINE-RELATED CANCER
- Phase 2 Trial of Single-agent Everolimus in Chemotherapy-naive Patients with Castration-resistant Prostate Cancer (SAKK 08/08)
- (2013) Arnoud J. Templeton et al. EUROPEAN UROLOGY
- Preclinical trial of a new dual mTOR inhibitor, MLN0128, using renal cell carcinoma tumorgrafts
- (2013) Alexandre Ingels et al. INTERNATIONAL JOURNAL OF CANCER
- Synergistic Targeting of PI3K/AKT Pathway and Androgen Receptor Axis Significantly Delays Castration-Resistant Prostate Cancer ProgressionIn Vivo
- (2013) Christian Thomas et al. MOLECULAR CANCER THERAPEUTICS
- Phase II trial of RAD001 and bicalutamide for castration-resistant prostate cancer
- (2012) Mari Nakabayashi et al. BJU INTERNATIONAL
- Safety and Preliminary Efficacy Analysis of the mTOR Inhibitor Ridaforolimus in Patients With Taxane-Treated, Castration-Resistant Prostate Cancer
- (2012) Robert J. Amato et al. Clinical Genitourinary Cancer
- Metformin and Prostate Cancer: Reduced Development of Castration-resistant Disease and Prostate Cancer Mortality
- (2012) Daniel E. Spratt et al. EUROPEAN UROLOGY
- Combination of Rad001 (Everolimus) and Propachlor Synergistically Induces Apoptosis through Enhanced Autophagy in Prostate Cancer Cells
- (2012) Sheng Tai et al. MOLECULAR CANCER THERAPEUTICS
- The translational landscape of mTOR signalling steers cancer initiation and metastasis
- (2012) Andrew C. Hsieh et al. NATURE
- The functions and regulation of the PTEN tumour suppressor
- (2012) Min Sup Song et al. NATURE REVIEWS MOLECULAR CELL BIOLOGY
- The natural history of metastatic progression in men with prostate-specific antigen recurrence after radical prostatectomy: long-term follow-up
- (2011) Emmanuel S. Antonarakis et al. BJU INTERNATIONAL
- Reciprocal Feedback Regulation of PI3K and Androgen Receptor Signaling in PTEN-Deficient Prostate Cancer
- (2011) Brett S. Carver et al. CANCER CELL
- Phase I Trial of Cixutumumab Combined with Temsirolimus in Patients with Advanced Cancer
- (2011) Aung Naing et al. CLINICAL CANCER RESEARCH
- End Points and Outcomes in Castration-Resistant Prostate Cancer: From Clinical Trials to Clinical Practice
- (2011) Howard I. Scher et al. JOURNAL OF CLINICAL ONCOLOGY
- Identification and Characterization of NVP-BKM120, an Orally Available Pan-Class I PI3-Kinase Inhibitor
- (2011) S.-M. Maira et al. MOLECULAR CANCER THERAPEUTICS
- Castration-Resistant Prostate Cancer: Targeted Therapies and Individualized Treatment
- (2011) R. Aggarwal et al. ONCOLOGIST
- Allosteric and ATP-competitive kinase inhibitors of mTOR for cancer treatment
- (2010) Carlos García-Echeverría BIOORGANIC & MEDICINAL CHEMISTRY LETTERS
- Integrative Genomic Profiling of Human Prostate Cancer
- (2010) Barry S. Taylor et al. CANCER CELL
- Phase IB Study of the mTOR Inhibitor Ridaforolimus With Capecitabine
- (2010) Antonella Perotti et al. JOURNAL OF CLINICAL ONCOLOGY
- Inhibitors of mTOR
- (2010) H.-J. Klumpen et al. ONCOLOGIST
- Steroid Hormone Receptors in Prostate Cancer: A Hard Habit to Break?
- (2009) Gerhardt Attard et al. CANCER CELL
- Differential Requirement of mTOR in Postmitotic Tissues and Tumorigenesis
- (2009) C. Nardella et al. Science Signaling
- Maintenance of Intratumoral Androgens in Metastatic Prostate Cancer: A Mechanism for Castration-Resistant Tumor Growth
- (2008) R. B. Montgomery et al. CANCER RESEARCH
- Pilot Study of Rapamycin in Patients with Hormone-Refractory Prostate Cancer
- (2008) Robert J. Amato et al. Clinical Genitourinary Cancer
- Docetaxel Plus Prednisone or Mitoxantrone Plus Prednisone for Advanced Prostate Cancer: Updated Survival in the TAX 327 Study
- (2008) Dominik R. Berthold et al. JOURNAL OF CLINICAL ONCOLOGY
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started